Could weight loss drug companies overtake fitness related companies on Wall Street?

The huge uptake of weight-loss drugs such as Ozempic and Wegovy is propelling their stocks to ever higher values. JP Morgan has predicted that sales of GLP-1 drugs will hit $100 billion by 2030 – perhaps not surprising given that a whopping 7 percent of the entire US population is expected to be using these drugs in the next 10 years.

At the same time fitness related companies such as Peloton (an internet-connected exercise equipment and media company whose shares peaked during lockdown) shares are waning in value.

We’ll just have to wait and see how this tracks over the next few years.